RecruitingNot ApplicableNCT04501419

Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria


Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

600 participants

Start Date

Oct 5, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to train Nigerian radiologists to perform ultrasound-guided breast biopsies on women that present to the hospital with a suspicious breast mass. Before performing biopsies on patients, the Nigerian radiologists will have already successfully completed a competency-based mobile health ultrasound-guided breast biopsy-training program. This program, developed by experts in Nigeria and the United States of America, certifies that they have the skills required to safely perform these biopsies on patients.


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria2

  • Age 18 and older female
  • Breast ultrasound demonstrating a solid mass that is suspicious for cancer, which would typically undergo either a blind biopsy or surgical excision at the Nigerian hospital where the patient is seeking diagnosis.

Exclusion Criteria2

  • Participants unwilling to sign consent
  • Participants under the age of 18.

Interventions

PROCEDUREUS-guided breast biopsy

During this study, women with undergo an US-guided breast biopsy by a radiologist instead of what is typically performed in Nigerian hospitals, which is either a blind biopsy or surgical excision. US-guided breast biopsy is the standard of care in the United States of America because the accuracy is better than blind biopsy and equal to surgical excision.

OTHERUltrasound-guided breast biopsy training program

This program, developed by experts in Nigeria and the United States of America, certifies that they have the skills required to safely perform these biopsies on patients


Locations(1)

Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC)

Ile-Ife, Nigeria

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04501419


Related Trials